17-iodoheptadecanoic-acid and Heart-Diseases

17-iodoheptadecanoic-acid has been researched along with Heart-Diseases* in 2 studies

Other Studies

2 other study(ies) available for 17-iodoheptadecanoic-acid and Heart-Diseases

ArticleYear
Effect of doxorubicin on [omega-I-131]heptadecanoic acid myocardial scintigraphy and echocardiography in dogs.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1983, Volume: 24, Issue:11

    The effects of serial treatment with doxorubicin on dynamic myocardial scintigraphy with [omega-I-131]heptadecanoic acid (I-131 HA), and on global left-ventricular function determined echocardiographically, were studied in a group of nine mongrel dogs. Total extractable myocardial lipid was compared postmortem between a group of control dogs and doxorubicin-treated dogs. A significant and then progressive fall in global LV function was observed at a cumulative doxorubicin dose of 4 mg/kg. A significant increase in the myocardial t1/2 of the I-131 HA was observed only at a higher cumulative dose, 10 mg/kg. No significant alteration in total extractable myocardial lipids was observed between control dogs and those treated with doxorubicin. Our findings suggest that the changes leading to an alteration of myocardial dynamic imaging with I-131 HA are not the initiating factor in doxorubicin cardiotoxicity.

    Topics: Animals; Dogs; Doxorubicin; Echocardiography; Fatty Acids; Heart; Heart Diseases; Lipid Metabolism; Microscopy, Electron; Myocardium; Radionuclide Imaging

1983
Myocardial imaging and metabolic studies with [17-123I]iodoheptadecanoic acid.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1980, Volume: 21, Issue:11

    After intravenous administration of the stearic acid analogue [17-123I]iodoheptadecanoic acid (I-123 HA), myocardial metabolism was studied in ten normal individuals, eight patients with coronary artery disease and three patients with congestive heart failure. High-quality images were obtained in sequential scintigraphy of I-123 metabolically bound in myocardial tissue. Infarcted zones as well as ischemic regions are indicated by reduced tracer uptake. Iodine-123 in the blood pool and interstitial space consists mainly of radioiodide that is liberated by fatty-acid metabolism and was corrected for. Using the proposed correction not only are the images improved but the uptake and elimination of the I-123 in the myocardial cells can be followed. The average disappearance half-time of I-123 HA from the myocardium of normal persons was 24 +/- 4.7 min. In patients with coronary artery disease significant differences between myocardial regions were observed.

    Topics: Adult; Aged; Coronary Disease; Fatty Acids; Fatty Acids, Nonesterified; Half-Life; Heart; Heart Diseases; Heart Failure; Humans; Iodine Radioisotopes; Male; Middle Aged; Myocardium; Radionuclide Imaging

1980